Skip to content
Peptide Evidence Registry

Comparison Centre

Two compounds, the same questions, no cherry-picking

Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.

Sharing keeps the two compounds you picked.

How to read these scores

Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.

  • Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
  • Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
  • Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
  • Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
  • Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.

None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.

Nafarelin

A GnRH agonist that has been an approved nasal-spray medicine for decades — the standing rebuttal to 'nasal peptide means research chemical'.

L5Repeated human trialsApproved for a specific indication · FDA (US)
Full profile

Triptorelin

A long-acting GnRH agonist depot used in prostate cancer and central precocious puberty.

L5Repeated human trialsApproved for a specific indication · FDA (US)
Full profile

How far human research has progressed

Nafarelin

Long-approved medicine with extensive clinical history

Triptorelin

Long-approved medicine across several formulations

Claim-specific benefit evidence

A human exposure study or trial registration does not establish that the claimed benefit occurs.

Nafarelin

Not separately assessed; see the full profile.

Triptorelin

Not separately assessed; see the full profile.

Human research context

Nafarelin

Long-approved medicine with extensive clinical history

Triptorelin

Long-approved medicine across several formulations

Human efficacy evidence strength

Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.

Nafarelin

Strength of the human efficacy evidence82 of 100 evidence strength

Triptorelin

Strength of the human efficacy evidence82 of 100 evidence strength

Preclinical (animal / lab) evidence strength

Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.

Nafarelin

Strength of the animal and lab evidence75 of 100 evidence strength

Triptorelin

Strength of the animal and lab evidence78 of 100 evidence strength

Human safety evidence strength

Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.

Nafarelin

Strength of the human safety evidence80 of 100 evidence strength

Triptorelin

Strength of the human safety evidence80 of 100 evidence strength

Regulatory status (legal position, not proof it works)

Nafarelin

Named regulators: FDA (US)

FDA-approved nasal solution (Synarel) for central precocious puberty; endometriosis labelling has varied by market and label revision. Approval is indication-specific.

Triptorelin

Named regulators: FDA (US)

Approved products cover indications including advanced prostate cancer and central precocious puberty, depending on formulation. Each product's approval is indication-specific.

Common claims

Nafarelin

  • · Manages central precocious puberty
  • · Historical use in endometriosis depending on market

Triptorelin

  • · Hormone suppression in prostate cancer
  • · Management of central precocious puberty

How settled our evidence rating is

Nafarelin

High confidence in ratingL5Repeated human trials

Triptorelin

High confidence in ratingL5Repeated human trials

Cancer-related questions raised by the biology

These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.

Nafarelin

No established human cancer signal within approved use.

Triptorelin

Used therapeutically in hormone-sensitive cancer; no established cancer-causing signal.

What this adds up to, in plain English

Nafarelin

Repeated large human trials support specific uses in the groups studied. That is strong evidence something works there — not proof it suits everyone or is free of risk.

Triptorelin

Repeated large human trials support specific uses in the groups studied. That is strong evidence something works there — not proof it suits everyone or is free of risk.

A comparison is not a recommendation

Neither column here is an endorsement, and the compound with the higher numbers is not the “better” or “safer” one — it is simply the one with more or better-quality research behind it. Two compounds can both be poorly evidenced, and better-evidenced says nothing about whether either is a sensible idea for a specific person. That is a conversation for a qualified clinician.